# US 2008/0287370 A1 · Boronic Acid Salts Useful in Parenteral Formulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0287370 A1
- Document ID: US20080287370A1
- Status: Published application
- Kind: A1
- Application number: 12/109,129
- Filed: 2008-04-24
- Published: 2008-11-20
- Earliest claimed: 2002-09-09
- Inventors: David Jonathan MADGE; Mark Dolman; Sophie Marie Combe-Marzelle; John Joseph Deadman; Anthony James Kennedy; Sanjay Kumar Kakkar
- Web page: https://patentgrep.com/patent/US20080287370A1

## CPC

- C07K 5/06078: {and aromatic or cycloaliphatic}
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/00: Drugs for disorders of the cardiovascular system
- C07K 5/06191: {containing heteroatoms different from O, S, or N}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Salts of a peptide boronic acid drug, for example of Cbz-(R)-Phe-(S)—Pro-(R)-Mpg-B(OH)2. The counter-ion to the boronate may be an alkali metal or derived from a strongly basic organic nitrogen-containing compound.

## Claims

### Claim 1

A parenteral pharmaceutical formulation comprising a therapeutically effective amount of a pharmaceutically acceptable base addition salt of a boronic acid of formula (I):
wherein
Y comprises a hydrophobic moiety which, together with the aminoboronic acid residue —NHCH(R9)—B(OH)2, has affinity for the substrate binding site of thrombin; and
R9 is a straight chain alkyl group interrupted by one or more ether linkages and in which the total number of oxygen and carbon atoms is 3, 4, 5 or 6 or R9 is —(CH2)m—W where m is from 2, 3, 4 or 5 and W is —H or halogen.

### Claim 2 (depends on 1)

The formulation of claim 1 wherein R9 is an alkoxyalkyl group.

### Claim 3 (depends on 1)

The formulation of claim 1 wherein YCO— comprises an amino acid residue which binds to the 52 subsite of thrombin, the amino acid residue being N-terminally linked to a moiety which binds the 53 subsite of thrombin.

### Claim 4 (depends on 1)

The formulation of claim 1 wherein Y comprises a dipeptide which binds to the S3 and S2 binding sites of thrombin.

### Claim 5 (depends on 4)

The formulation of claim 4 wherein the 53-binding amino acid residue is of (R)-configuration, the 52-binding residue Is of (S)-configuration, and the fragment —NHCH(R9)—B(OH) is of (R)-configuration.

### Claim 6 (depends on 1)

The formulation of claim 1 wherein R9 is an alkoxyalkyl group.

### Claim 7 (depends on 1)

The formulation of claim 1 wherein the boronic acid has a Ki for thrombin of about 100 nM or less.

### Claim 8 (depends on 1)

The formulation of claim 1 wherein the salt comprises a salt of the boronic acid with metal or a strongly basic organic nitrogen-containing compound.

### Claim 9 (depends on 1)

The formulation of claim 1 wherein the salt comprises a salt of the boronic acid with an alkali metal, an aminosugar, a guanidine or an amine of formula (XI):
where n is from 1 to 6, R2 is H, carboxylate or derivatised carboxylate, R3 is H, C1-C4 alkyl or a residue of a natural or unnatural amino acid.

### Claim 10 (depends on 4)

The formulation of claim 4 wherein the Y dipeptide is N-terminally protected or N-terminally unprotected, and the peptide linkages in the dipeptide are unsubstituted or independently N-substituted by a C1-C13 hydrocarbyl, wherein the C1-C13 hydrocarbyl contains no heteratoms or at least one in-chain or in-ring nitrogen, oxygen or sulfur atom, and the C1-C13 hydrocarbyl is unsubstituted or substituted by a substituent selected from halo, hydroxy and trifluoromethyl.

### Claim 11 (depends on 1)

The formulation of claim 1 wherein the salt consists essentially of an acid salt in which one B—OH group of formula (I), when trigonally represented, remains protonated.

### Claim 12 (depends on 9)

The formulation of claim 9 wherein the salt comprises boronate ions derived from the peptide boronic acid and has a stoichiometry consistent with the boronate ions carrying a single negative charge.

### Claim 13 (depends on 6)

The formulation of claim 6 wherein the salt consists essentially of a monosodium or monolithium salt of the boronic acid.

### Claim 14 (depends on 9)

The pharmaceutical formulation of claim 9 which is adapted for intravenous administration.

### Claim 15

A formulation in parenteral dosage form comprising a therapeutically effective amount of a pharmaceutically acceptable base addition salt of a boronic acid of formula (II):
where:
X is H or an amino-protecting group;
aa1 is an amino acid residue having a hydrocarbyl side chain containing no more than 20 carbon atoms and comprising at least one cyclic group having up to 13 carbon atoms;
aa2 is an imino acid residue having from 4 to 6 ring members;
R1 is a group of the formula —(CH2)s-Z, where s is 2, 3 or 4 and Z is —OH, —OMe, —OEt or halogen.

### Claim 16 (depends on 15)

The formulation of claim 15 wherein aa1 is selected from Phe, Dpa and wholly or partially hydrogenated analogues thereof.

### Claim 17 (depends on 16)

The formulation of claim 16 wherein aa1 is of R-configuration.

### Claim 18 (depends on 15)

The formulation of claim 15 wherein aa2 is a residue of an imino add of formula (IV)
where R1 is —CH2—, —CH2—CH2—, —S—CH2—, —S—C(CH3)2— or —CH2—CH2—CH2—, and, when the formula (IV) ring is 5- or 6-membered, the formula (IV) ring is unsubstituted or is substituted at one or more —CH2— groups by from 1 to 3 C1-C3 alkyl groups.

### Claim 19 (depends on 18)

The formulation of claim 18 wherein aa2 is of S-configuration.

### Claim 20 (depends on 15)

The formulation of claim 15, wherein aa1-aa2 is (R)-Phe-(S)—Pro and the fragment —NH—CH(R1)—B(OH)2 is of R-configuration.

### Claim 21 (depends on 16)

The formulation of claim 16 wherein the boronic acid Is of formula (VIII):
X—(R)-Phe-(S)—Pro-(R)-Mpg-B(OH)2 (VIII),
wherein X is R6—(CH2)P—C(O)—, R6—(CH2)p—S(O)2—, R6—(CH2)p—NH—C(O)— or R6—(CH2)p—O—C(O)-wherein p is 0, 1, 2, 3, 4, 5 or 6 and R6 is H or a 5 to 13-membered cyclic group which is unsubstituted or substituted by 1, 2 or 3 substituents selected from halogen; amino; nitro; hydroxy; a C5-C6 cyclic group; C1-C4 alkyl and C1-C4 alkyl containing, or linked to the cyclic group through, an in-chain O atom, the aforesaid alkyl groups optionally being substituted by a substituent selected from halogen, amino, nitro, hydroxy and a C5-C6 cyclic group.

### Claim 22 (depends on 16)

The formulation of claim 16 wherein the salt comprises a salt of the boronic acid with an alkali metal, an aminosugar or an amine of formula (XI):
where n is from 1 to 6, R2 is H, carboxylate or derivatised carboxylate, R3 is H, C1-C4 alkyl or a residue of a natural or unnatural amino acid.

### Claim 23

A pharmaceutical product comprising a sealed container containing in the form of a finely divided solid, ready for reconstitution to form a liquid parenteral formulation, a therapeutically effective amount of a boronate salt which consists essentially of a single pharmaceutically acceptable base addition salt of a boronic add formula (II):
where:
X is H or an amino-protecting group;
aa1 is an amino acid residue of R-configuration having a hydrocarbyl side chain containing no more than 20 carbon atoms and comprising at least one cyclic group having up to 13 carbon atoms;
aa2 is an imino acid residue of S-configuration having from 4 to 6 ring members;
C* is a chiral centre of R-configuration; and
R1 is a group of the formula —(CH2)s-Z, where s is 2, 3 or 4 and Z is —OH, —OMe, —OEt or halogen.

### Claim 24

A pharmaceutical formulation adapted for parenteral administration, whether directly or after combining with a liquid, and comprising
a) a first species selected from a boronic acid of formula (I), and boronate ions of said boronic acid and equilibrium forms of said boronic acid and said boronate ions:
wherein
Y comprises a hydrophobic moiety which, together with the aminoboronic acid residue —NHCH(R9)—B(OH)2, has affinity for the substrate binding site of thrombin; and
R9 is a straight chain alkyl group interrupted by one or more ether linkages and in which the total number of oxygen and carbon atoms is 3, 4, 5 or 6 or R9 is —(CH2)m—W where m is from 2, 3, 4 or 5 and W is —OH or halogen; and
(b) a second species selected from pharmaceutically acceptable metal ions, said metal ions having a valency of n, lysine, arginine and aminosugars,
wherein the formulation has an observed stoichiometry of first to second species essentially consistent with a notional stoichiometry of 1:1 when the second species is a metal ion with a valency of 1 or is lysine, arginine or an aminosugar, or an observed stoichiometry of n:1 when the second species is a metal ion with a valency of greater than 1.

### Claim 25 (depends on 1)

A method of inhibiting thrombin in the prophylaxis or therapy of disease, comprising parenterally administering to a mammal suffering from, or at risk of suffering from, thrombosis a therapeutically effective amount of the salt defined in claim 1.

### Claim 26 (depends on 16)

A method for preventing thrombosis in a haemodialysis circuit of a patient, for preventing a cardiovascular event In a patient with end stage renal disease, for preventing venous thromboembolic events in a patient receiving chemotherapy through an indwelling catheter, for preventing thromboembolic events in a patient undergoing a lower limb arterial reconstructive procedure, or for treating by way of therapy or prophylaxis an arterial disease selected from acute coronary syndromes, cerebrovascular thrombosis, peripheral arterial occlusion and arterial thrombosis resulting from atrial fibrillation, valvular heart disease, arterio-venous shunts, indwelling catheters or coronary stents, the method comprising parenterally administering to a mammal a therapeutically effective amount of the salt defined in claim 16.

### Claim 27 (depends on 1)

A method for making a salt of claim 1, comprising:
combining in a solvent diethanolamine and an ester of a boronic acid as defined in claim 1;
allowing or causing a precipitate to form and recovering the precipitate;
converting the precipitated material into the free organoboronic acid by contacting the precipitated material with an aqueous acid or base; and
reacting the organoboronic acid with a base of a pharmaceutically acceptable multivalent metal to form to a salt as defined in claim 1.

### Claim 28

A medicament adapted for parenteral administration and comprising a therapeutically effective amount of a pharmaceutically acceptable base addition salt of a boronic acid which is a selective thrombin Inhibitor and has a neutral aminoboronic acid residue capable of binding to the thrombin S1 subsite linked through a peptide linkage to a hydrophobic moiety capable of binding to the thrombin S2 and 53 subsites, the salt comprising a cation having a valency n and having an observed stoichiometry consistent with a notional stoichiometry (boronic acid:cation) of n: 1.

### Claim 29 (depends on 28)

A medicament of claim 28 wherein the boronic acid has a Ki for thrombin of about 100 nM or less.
